Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3 Neoplasms 2 Breast Neoplasms 2 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Ototoxicity 1 Heart Failure 1 Endometrial Neoplasms 1 Endometrial Hyperplasia 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Atherosclerosis 1

Interventions

Gemcitabine 406 Oxaliplatin 131 Fluorouracil 125 130-nm albumin-bound paclitaxel 108 Capecitabine 100 Albumin-Bound Paclitaxel 90 Leucovorin 88 Irinotecan 87 Radiotherapy 76 Radiosurgery 64 Taxes 63 Cisplatin 56 Erlotinib Hydrochloride 44 Drug Therapy 42 folfirinox 40 Magnetic Resonance Spectroscopy 39 pembrolizumab 35 Blood Specimen Collection 33 S 1 (combination) 31 Pancreaticoduodenectomy 31 Docetaxel 31 Nivolumab 30 Bevacizumab 30 Biopsy 26 Surgical Procedures, Operative 25 Cyclophosphamide 25 irinotecan sucrosofate 24 Specimen Handling 24 Radiation 22 Standard of Care 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pancreatic Neoplasms × Hydroxymethylglutaryl-CoA Reductase Inhibitors × Clear all

NCT04245644 2024-03-12

CAOS

IRCCS San Raffaele

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡